14 August 2017

Notice of interim results

 

London, UK – 14 August 2017: Ergomed plc (LSE: ERGO) ('Ergomed' or the ‘Company'), a specialised pharmaceutical services and drug development company, will announce its Interim Results for the six months ended 30 June 2017 on Monday 18 September 2017.

 

Dr Dan Weng, Chief Executive Officer, and Stephen Stamp, Chief Financial Officer, will host a presentation and conference call for analysts at 9:00am BST on the day of the results at the offices of Numis Securities, The London Stock Exchange Building, 10 Paternoster Square, London, EC4M 7LT.

 

ENDS

 

Enquiries:

 

Ergomed plc

Tel: +44 (0) 1483 503205

Dan Weng (Chief Executive Officer)

 

Stephen Stamp (Chief Financial Officer)

 

 

 

Numis Securities Limited

Tel: +44 (0) 20 7260 1000

Michael Meade / Freddie Barnfield (Nominated Adviser)

 

James Black (Joint Broker)

 

 

 

N+1 Singer

Tel: +44 (0) 20 7496 3000

Alex Price (Joint Broker)

 

 

 

Consilium Strategic Communications – for UK enquiries

Tel: +44 (0) 20 3709 5700

Chris Gardner / Mary-Jane Elliott

Ivar Milligan / Philippa Gardner

ergomed@consilium-comms.com

 

 

MC Services – for Continental European enquiries

Tel: +49 211 5292 5222

Anne Hennecke

 

     

 

 

About Ergomed

Ergomed provides specialist services to the pharmaceutical industry and develops drugs both wholly-owned and through partnerships. Ergomed’s fast-growing, profitable service offering spans all phases of clinical development and post-approval pharmacovigilance and medical information. Drawing on more than 20 years of expertise in drug development, Ergomed is also building a growing portfolio of drug development partnerships and programmes, including wholly-owned proprietary products for the treatment of surgical bleeding. For further information, visit: http://ergomedplc.com.


Back to previous page